Just months after cutting 23% of its workforce, Viracta Therapeutics let go of 42% of employees as it increased focus on lead product candidate nana-val in lymphoma patients. The Cardiff, California, biotech announced the latest layoffs Nov. 6. An SEC filing that same day stated the cuts were effective Oct. 31.
The company’s board makeup also decreased Oct. 31 with the voluntary resignations of four of its 10 directors, according to the announcement.
Viracta had 40 full-time employees as of March 31, as stated in a May SEC filing. Based on cutting 23% of staff in August and 42% in October, the biotech now has about 18 employees.
https://www.biospace.com/job-trends/viracta-therapeutics-cuts-42-of-staff-as-part-of-resource-reprioritization